Kombination aus Brentuximab-Vedotin und hautspezifischen Therapien verlängert bei Patienten mit kutanem T-Zell-Lymphom die Zeit bis zur nächsten Therapieeskalation.
- DOI
- 10.1111/ddg.14342_g
- Published
- 2021 Mar
- Container
- Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/ddg.14342_g,
title = {Kombination aus Brentuximab-Vedotin und hautspezifischen Therapien verlängert bei Patienten mit kutanem T-Zell-Lymphom die Zeit bis zur nächsten Therapieeskalation.},
author = {Stranzenbach R and Stadler R},
year = {2021},
journal = {Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG},
doi = {10.1111/ddg.14342_g},
url = {https://doi.org/10.1111/ddg.14342_g}
}RIS
TY - JOUR TI - Kombination aus Brentuximab-Vedotin und hautspezifischen Therapien verlängert bei Patienten mit kutanem T-Zell-Lymphom die Zeit bis zur nächsten Therapieeskalation. AU - Stranzenbach R AU - Stadler R PY - 2021 JO - Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG DO - 10.1111/ddg.14342_g UR - https://doi.org/10.1111/ddg.14342_g ER -
APA
R, S., & R, S. (2021). Kombination aus Brentuximab-Vedotin und hautspezifischen Therapien verlängert bei Patienten mit kutanem T-Zell-Lymphom die Zeit bis zur nächsten Therapieeskalation.. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. https://doi.org/10.1111/ddg.14342_g
Source records
- pubmed · retrieved 2026-09-25T08:58:39.320Z